Table 2 Comparison between patients with or without androgen deficiency
From: Androgen deficiency is associated with a better prognosis in glioblastoma
Androgenic deficiency | p-value | ||
|---|---|---|---|
No (n = 17) | Yes (n = 18) | ||
Age (years) | 62.71 (SD = 11.58) | 65.39 (SD = 8.68) | 0.5251 |
Gender (male:female) | 8:9 | 13:5 | 0.1762 |
Karnofsky < 70 | 1 (5.9%) | 2 (11.1%) | 1.0002 |
Resection | |||
Biopsy/partial | 6 (35.3%) | 4 (22.2%) | 0.6922 |
Subtotal | 3 (17.6%) | 4 (22.2%) | |
Total | 8 (47.1%) | 10 (55.6%) | |
Ki67 | 26.29 (SD = 13.16) | 29.33 (SD = 21.31) | 0.9701 |
MGMT methylation | 8 (50.0%) | 9 (50.0%) | 1.0002 |
Pattern of contrast enhancement | |||
Peripheric | 8 (47.1%) | 12 (66.7%) | 0.3152 |
Heterogeneous | 9 (52.9%) | 6 (33.3%) | |
Enhancing tumor (cc) | 22.36 (SD = 19.11) | 23.53 (SD = 11.58) | 0.4651 |
Edema (cc) | 59.78 (SD = 37.34) | 51.20 (SD = 33.11) | 0.5331 |
Necrosis (cc) | 9.99 (SD = 11.33) | 9.79 (SD = 10.62) | 0.9861 |
Necrosis-to-contrast ratio | 0.57 (SD = 0.74) | 0.36 (SD = 0.28) | 0.7361 |
AR expression (WB) (Z-value) | 0.11 (SD = 1.07) | -0.12 (SD = 1.10) | 0.8181 |
AR-Score (Z-value) | -1.15 (SD = 4.12) | 0.11 (SD = 1.38) | 0.2511 |
ARn/t fluorescence | 0.16 (SD = 0.04) | 1.28 (SD = 3.48) | 0.5731 |
Progression-free survival (days) | 135.0 [90.5–179.5] | 252.0 [0–720.8] | 0.0413 |
Men | 200.0 [94.6–305.4] | 252.0 [0–735.8] | 0.1553 |
Women | 105.0 [88.8–121.2] | 286.0a [32.2–540.8] | 0.4423 |
Overall survival (days) | 314.0 (95.2–532.8] | 864.0 [333.9–1394.1] | 0.1563 |
Men | 314 [293.2–334.8] | 406.0 [256.8–555.2] | 0.2573 |
Womenb | – | – | – |